Drug Boosts Immune Cells Against Melanoma in Lab

UCLA researchers found temporarily raising p53 activity helped exhausted T cells better target melanoma cells in laboratory tests.

Updated on Nov. 2, 2026 in Cancer

Cell culture flasks and a petri dish of amber liquid on a steel lab bench in a bright laboratory, with pipette tips nearby. — UCLA researchers reported that the experimental drug navtemadlin reduced T cell exhaustion and improved melanoma cell killing in laboratory tests, published in Frontiers in Immunology. AI Illustration. Upload story photo >

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center reported that treating human T cells with the experimental drug navtemadlin reduced exhaustion and improved their ability to kill melanoma cells in the lab. The study was published in Frontiers in Immunology.

Why it matters

Some cancer treatments modify a patient's T cells so they recognize tumors, but these cells can lose effectiveness over time. The findings suggest a way to keep T cells active longer, a challenge for future immune-based cancer therapies.

The experiments used human cells in a dish, with no animal or human testing reported, and the significance figures were drawn against untreated T cells in the same lab setup. Whether these lab gains translate to clinical benefit remains unknown.

The players

UCLA Health Jonsson Comprehensive Cancer Center

A major cancer research center affiliated with the University of California, Los Angeles, where the study was conducted.

The details

Researchers treated human T cells with navtemadlin, a drug that temporarily increases activity of p53, a protein that helps prevent cancer, during the lab manufacturing step when patient T cells are prepared. The treated cells showed more energy and fewer signs of exhaustion than untreated cells.

Article about the p53 immune cell study published November 2, 2026.

Big Picture

The work builds on the Jonsson center's longstanding T cell research, extending it toward reducing the exhaustion that limits engineered T cell therapies in solid tumors. It remains preclinical, so its practical role in current treatment is still unproven.

Patients receiving T cell therapies could eventually see treatments that keep immune cells effective longer, but this is not available now. For current cancer patients in California and elsewhere, existing treatment decisions remain unchanged by this laboratory work.

The takeaway

Lab results on T cell exhaustion are an early step, and animal and clinical testing will determine whether this approach can help patients. Readers should treat the findings as promising but preliminary.